Managing HPV: A New Era in Patient Care: External Genital Warts

Learning Objectives

Participants of this activity will be able to:

• Identify the natural history of external genital warts (EGW)
• Discuss provider- and patient-applied EGW treatment modalities
• Identify factors to consider when selecting EGW treatment

Accreditation Information

Nurse Practitioners and Nurses: This educational activity has been approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health for 1 contact hour, including 1 pharmacology hour. Credit can be applied toward the nursing continuing requirements of most professional organizations and State Boards of Nursing.

Pharmacists: The Association of Reproductive Health Professionals (ARHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hour of continuing education credit. The assigned universal program number for Managing HPV: A New Era in Patient Care – External Genital Warts is 463-000-09-010-H04-P.

Others: A certificate of attendance will be issued indicating that this activity is accredited for 1 hour of AMA PRA Category 1 Credit^TM.

Sponsoring Information

This program is sponsored by the Association of Reproductive Health Professionals. It is being done in conjunction with Planned Parenthood^® Federation of America.

Funding Information

The Managing HPV program is funded through educational grants from a collaboration of companies including GlaxoSmithKline, Graceway Pharmaceuticals, Merck and Co. Inc., Roche Pharmaceuticals, and QIAGEN.

Disclosure Information

All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.

Advisory Committee Disclosures

• Nancy Berman, MSN, APRN, BC: Speaker for Digene Corporation, Graceway Pharmaceuticals, and Merck and Co., Inc. ; Consultant for Digene Corporation
• Barbara J.B. Clark, MPAS, PA-C : S peaker for Ortho Women’s Health and Urology, and Wyeth Pharmaceuticals
• Don Downing, R.Ph: No affiliations to disclose
• Francisco Garcia, MD, MPH (Chair): No affiliations to disclose
• Sherri Sheinfeld Gorin, PhD: No affiliations to disclose
• Maura Gillison, MD, PhD: Receives unrestricted educational grants from Merck and Digene.
• Anna R. Giuliano, PhD: Speaker and consultant for Merck and Co., Inc; Speaker for GlaxoSmithKline; Receives grant/research support from Merck and Co., Inc.
• Richard Guido, MD: Conducted research for Graceway Pharmaceuticals and Tigress Pharmaceuticals; Speaker f or Merck and Co., Inc.; Consultant for GlaxoSmithKline
• Julie Hibben, LMSW, CPSI : No affiliations to disclose
• Joel Palefsky, MD: Receives grant/research support from Merck and Co.; Consultant for GSK
• Mary Rubin, RNC, PhD, CRNP: Speaker for Digene Corporation and Merck and Co., Inc.
• Marie Savard, MD: Speaker for Digene Corporation and GlaxoSmithKline
• Anafidelia Tavares, MD: Receives unrestricted educational grants from Merck and Digene
• Maria Trent, MD: Speaker for Merck and Co., Inc. Medical Forums
• Jeffrey Waldman, MD: Speaker for Digene Corporation, Graceway Pharmaceuticals, and GlaxoSmithKline
• Thomas C. Wright, MD: Consultant for GlaxoSmithKline, Merck and Co., Inc. and Roche Molecular Systems, Inc.

ARHP Staff/Consultant Disclosures

• Vanessa Cullins, MD: Receives grants and research support from Digene Corporation, Graceway Pharmaceuticals, Merck and Co., Inc., and Ortho Women’s Health, Urology Wyeth Pharmaceuticals; consultant for Merck and Co., Inc.; speaker for Ortho Women’s Health and Urology
• Camille V. Harris, MPH, Diane Shannon, MD, MPH, Wayne Shields, Amy Swann, MA, and Sandy Worthington MSN, CNM, RNC have no affiliations to disclose